The report will be delivered in 2-3 business days.

Bladder Cancer Drugs Global Market Report 2019

Starting Price : $ 4000.00 | Pages : 200 | Published : December 2019 | SKU CODE : 7214 | Format :


The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others.

The global bladder cancer drugs market was valued at about $0.3 billion in 2018 and is expected to grow to $0.32 billion at a CAGR of 1.9% through 2022.

North America was the largest region in the bladder cancer drugs market in 2016, followed by Europe. This region is expected to remain the largest during the next five years. The bladder cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer. According to American Cancer Society, the number of new bladder cancer cases increased by 20.3% in the USA and the number of new bladder cancer cases is estimated to reach 80,470 by the end of 2019 in the country. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market.

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, in 2016, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the centre for drug research and development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology.

The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

Major players in the market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb

    1. Executive Summary

    2. Bladder Cancer Drugs Market Characteristics

    3. Bladder Cancer Drugs Market Size And Growth

    3.1. Global Bladder Cancer Drugs Historic Market, 2014 - 2018, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Bladder Cancer Drugs Forecast Market, 2018 - 2022F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Bladder Cancer Drugs Market Segmentation

    4.1. Global Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Non-Muscle-Invasive Bladder Cancer

    Muscle-Invasive Bladder Cancer

    4.2. Global Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Low-Grade Tumors

    High-Grade Tumors

    5. Bladder Cancer Drugs Market Regional And Country Analysis

    5.1. Global Bladder Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    5.2. Global Bladder Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Bladder Cancer Drugs Market  

    6.1. Asia-Pacific Bladder Cancer Drugs Market Overview  

    6.2. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    7. China Bladder Cancer Drugs Market  

    7.1. China Bladder Cancer Drugs Market Overview  

    7.2. China Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    7.3. China Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    8. India Bladder Cancer Drugs Market  

    8.1. India Bladder Cancer Drugs Market Overview  

    8.2. India Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    8.3. India Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9. Japan Bladder Cancer Drugs Market  

    9.1. Japan Bladder Cancer Drugs Market Overview  

    9.2. Japan Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9.3. Japan Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10. Australia Bladder Cancer Drugs Market  

    10.1. Australia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10.2. Australia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11. Indonesia Bladder Cancer Drugs Market  

    11.1. Indonesia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11.2. Indonesia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12. South Korea Bladder Cancer Drugs Market  

    12.1. South Korea Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12.2. South Korea Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13. Western Europe Bladder Cancer Drugs Market  

    13.1. Western Europe Bladder Cancer Drugs Market Overview

    13.2. Western Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13.3. Western Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14. UK Bladder Cancer Drugs Market  

    14.1. UK Bladder Cancer Drugs Market Overview

    14.2. UK Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14.3. UK Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15. Germany Bladder Cancer Drugs Market  

    15.1. Germany Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15.2. Germany Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16. France Bladder Cancer Drugs Market  

    16.4. France Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16.5. France Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17. Eastern Europe Bladder Cancer Drugs Market  

    17.1. Eastern Europe Bladder Cancer Drugs Market Overview

    17.2. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18. Russia Bladder Cancer Drugs Market  

    18.1. Russia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18.2. Russia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19. North America Bladder Cancer Drugs Market  

    19.1. North America Bladder Cancer Drugs Market Overview

    19.2. North America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19.3. North America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20. USA Bladder Cancer Drugs Market  

    20.1. USA Bladder Cancer Drugs Market Overview

    20.2. USA Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20.3. USA Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21. South America Bladder Cancer Drugs Market  

    21.1. South America Bladder Cancer Drugs Market Overview

    21.2. South America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21.3. South America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22. Brazil Bladder Cancer Drugs Market  

    22.1. Brazil Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22.2. Brazil Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23. Middle East Bladder Cancer Drugs Market  

    23.1. Middle East Bladder Cancer Drugs Market Overview

    23.2. Middle East Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23.3. Middle East Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24. Africa Bladder Cancer Drugs Market  

    24.1. Africa Bladder Cancer Drugs Market Overview

    24.2. Africa Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24.3. Africa Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    25. Bladder Cancer Drugs Market Competitive Landscape And Company Profiles

    25.1. Bladder Cancer Drugs Market Competitive Landscape

    25.2. Bladder Cancer Drugs Market Company Profiles

    25.2.1. Pfizer

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Celgene Corporation

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Eli Lilly

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. AstraZeneca

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Bristol-Myers Squibb

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Bladder Cancer Drugs Market

    27. Bladder Cancer Drugs Market Trends And Strategies

    28. Product Pipeline Analysis

    29. Bladder Cancer Drugs Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
  • Table 3: Global Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 4: Global Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 5: Global Bladder Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 6: Global Bladder Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 9: China, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 10: China, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 11: India, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 12: India, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 13: Japan, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 15: Australia, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 17: Indonesia, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 19: South Korea, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 21: Western Europe, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 23: UK, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 24: UK, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 25: Germany, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 27: France, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 28: France, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 29: Eastern Europe, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 31: Russia, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 33: North America, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 34: North America, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 35: USA, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 36: USA, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 37: South America, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 38: South America, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 39: Brazil, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 41: Middle East, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 43: Africa, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 45: Pfizer Financial Performance
  • Table 46: Celgene Corporation Financial Performance
  • Table 47: Eli Lilly Financial Performance
  • Table 48: AstraZeneca Financial Performance
  • Table 49: Bristol-Myers Squibb Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Figure 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
  • Figure 3: Global Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 4: Global Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 5: Global Bladder Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 6: Global Bladder Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 9: China, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 10: China, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 11: India, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 12: India, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 13: Japan, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 15: Australia, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 17: Indonesia, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 19: South Korea, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 21: Western Europe, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 23: UK, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 25: Germany, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 27: France, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 28: France, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 29: Eastern Europe, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 31: Russia, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 33: North America, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 35: USA, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 37: South America, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 39: Brazil, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 41: Middle East, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 43: Africa, Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 45: Pfizer Financial Performance
  • Figure 46: Celgene Corporation Financial Performance
  • Figure 47: Eli Lilly Financial Performance
  • Figure 48: AstraZeneca Financial Performance
  • Figure 49: Bristol-Myers Squibb Financial Performance
Research And Development Initiatives Taken In The Anti-Infective Drugs Market
Research Initiatives And Funding And Demand For New Medicines For Drug-Resistant Infections In The Anti-Infective Drugs Industry
Global Biologics Market, Opportunities And Strategies Market | Characteristics, Forecast Size, Trends
Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions and By Key Players - Global Forecast To 2021
View Report
Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022
View Report
Cardiovascular Drugs Global Market Report 2019
View Report
Dermatology Drugs Global Market Report 2019
View Report
Gastrointestinal Drugs Global Market Report 2019
View Report
Hematology Drugs Global Market Report 2019
View Report
Metabolic Disorders Drugs Global Market Report 2019
View Report
Musculoskeletal Disorders Drugs Global Market Report 2019
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)